Toxicology Program to Support Initiation of a Clinical Phase I Program for a New Medicine

Early Drug Development: Strategies and Routes to First-in-Human Trials

Volumn , Issue , 2010, Pages 281-307

  Black, Hugh E ^a   Montgomery, Stephen B ^a   Moch, Ronald W ^b  

^a Hugh E Black Associates Inc   (United States)

^b Hugh E Black Associates Inc   (United States)

Author keywords

Good laboratory practice (GLP) toxicology program; Planning for toxicity studies and appropriate protocol development; Toxicology program, supporting clinical Phase I program initiation for a new medicine

Indexed keywords

EID: 84885564354     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470613191.ch7     Document Type: Chapter

References (24)

1. Serabian MA, Pilaro AM. Safety assessment of biotechnology-derived pharmaceuticals. ICH and beyond. Toxicol Pathol. 1999;27:27-31.
2. Medjitna TD, Stadler C, Bruckner L, Griot C, Ottiger HP. DNA vaccines: safety aspect assessment and regulation. Dev Biol. 2006;126:261-207.
3. ICH Safety Guidelines: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. ICH S6 (1997); ICH S6(R1) (2008). International Conference on Harmonization. Available at: www.ich.org.
4. Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev/Drug Discov. 2007;6:636-648.
5. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32:56-67.
6. Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev/Drug Discov. 2004;3:226-236.
7. ICH Quality Guideline: Impurities in New Drug Products. ICH Q3B(R2). International Conference on Harmonization; 2006. Available at: www.ich.org.
8. Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches. U.S. Department of Health and Human Services, Food and Drug Administration; 2008.
9. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2005.
10. Guidance for Industry: Safety Testing of Drug Metabolites. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2008.
11. Ames BN, McCann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975;31:347-364.
12. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983;113:173-215.
13. ICH Multidisciplinary Guideline: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. ICH M3. International Conference on Harmonization; 1997. Available at: www.ich.org.
14. ICH Multidisciplinary Guideline: Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. International Conference on Harmonization; ICH M3(R1). 1997. Available at: www.ich.org.
15. ICH Multidisciplinary Guideline: Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. ICH M3(R2). International Conference on Harmonization; 2008. Available at: www.ich.org.
16. ICH Safety Guideline: Duration of Chronic Toxicity Testing in Animals (Rodent and Non-rodent Toxicity Testing). ICH S4. International Conference on Harmonization; 1999. Available at: www.ich.org.
17. ICH Safety Guideline: Detection of Toxicity to Reproduction for Medicinal Products and Toxicity to Male Fertility. ICH S5(R2). International Conference on Harmonization; 1994. Available at: www.ich.org.
18. ICH Safety Guideline: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals. ICH S1A. International Conference on Harmonization; 1996. Available at: www.ich.org.
19. ICH Safety Guideline: Testing for Carcinogenicity of Pharmaceuticals. ICH S1B. International Conference on Harmonization; 1998. Available at: www.ich.org.
20. ICH Safety Guideline: Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. ICH S2(R1). International Conference on Harmonization; 2008. Available at: www.ich.org.
21. ICH Safety Guideline: Immunotoxicity Studies for Human Pharmaceuticals. ICH S8. International Conference on Harmonization; 2006. Available at: www.ich.org.
22. Center for Food Safety and Applied Nutrition's Redbook. U.S. Food and Drug Administration. Available at: www.cfsan.fda.gov/~redbook/red-ivb1.html.
23. Eaton DL, Klaassen CD. Principles of toxicology. In: Klaasen CD, ed. Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th ed. New York: McGraw-Hill, Chap. 24.
24. DeGeorge JJ, et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol. 1998;41:173-185.